Modalert (Modafinil) Tablets: Uses, Dosage and Safety Information

Modalert is a brand of oral tablets containing modafinil, a prescription wakefulness-promoting medicine used for certain diagnosed sleep disorders. It is primarily considered when excessive daytime sleepiness interferes with normal daytime function despite appropriate management of the underlying condition. We offer Modalert in 100 mg and 200 mg strengths, with packages containing 30 to 360 tablets. This guide explains the medicine's established uses, effects, general dosage principles, safety considerations and place among other treatment options.

What is Modalert?

Modalert contains modafinil as its active ingredient. Modafinil is classed as a wakefulness-promoting agent and acts on the central nervous system to support alertness during usual waking hours. It is chemically distinct from amphetamine-based stimulants, although both types of medicine can influence brain pathways involved in arousal and attention.

The current product is an immediate-release oral tablet available in 100 mg and 200 mg strengths. We offer packages of 30, 60, 90, 120, 180, 270 and 360 tablets in each strength. The appropriate strength, number of tablets and duration of treatment depend on the diagnosed condition and the prescriber's instructions rather than package size alone.

Modafinil promotes wakefulness but does not replace sleep. It is not intended to compensate for voluntary sleep deprivation, occasional tiredness, jet lag or an unsafe work schedule. Persistent sleepiness requires medical assessment because it can arise from sleep disorders, medicines, mental health conditions, neurological illness or other medical causes.

Excessive daytime sleepiness and sleep disorders

Excessive daytime sleepiness is more than feeling tired after a late night. It can involve an uncontrollable tendency to fall asleep, repeated lapses in alertness, difficulty concentrating and impaired performance even when a person appears to have had enough opportunity to sleep. These symptoms can affect work, study, relationships and safety, particularly when driving or operating machinery.

Narcolepsy is a neurological sleep disorder that disrupts the normal regulation of sleep and wakefulness. In addition to severe daytime sleepiness, some people experience sudden loss of muscle tone triggered by emotion, sleep paralysis, vivid dream-like experiences around sleep or fragmented night-time sleep. Modafinil may improve daytime wakefulness, but it does not treat every symptom of narcolepsy.

Obstructive sleep apnoea causes repeated narrowing or closure of the upper airway during sleep. Continuous positive airway pressure (CPAP) and other measures directed at the airway remain the primary treatments. A wakefulness-promoting medicine may be considered only when clinically important sleepiness persists despite effective treatment and adequate sleep.

Shift work sleep disorder can occur when a work schedule repeatedly conflicts with the body's usual sleep-wake rhythm. Management may include changes to shift patterns, protected sleep time and appropriately timed light exposure. Medicine does not make an unsafe or chronically sleep-restricting schedule harmless.

How modafinil works

The full mechanism of modafinil has not been established. It inhibits dopamine reuptake by binding to the dopamine transporter, which increases dopamine signalling in parts of the brain involved in wakefulness. It also influences other arousal systems, including pathways involving noradrenaline, histamine, glutamate, gamma-aminobutyric acid and the hypothalamus.

These combined effects support wakefulness without acting through exactly the same mechanism as conventional amphetamine stimulants. This distinction does not mean that modafinil is free from stimulant-like adverse effects. It can still cause insomnia, anxiety, a faster heartbeat or increased blood pressure, and it requires appropriate medical supervision.

After an oral dose, modafinil is absorbed and usually reaches its highest blood concentration within several hours. Food does not substantially reduce the amount absorbed, but a meal may delay the time taken to reach the peak concentration. The practical onset and duration of alerting effects vary between individuals and can also be influenced by dose timing, liver function and interacting medicines.

What clinical evidence shows

Clinical studies have found that modafinil can reduce subjective sleepiness and improve performance on structured tests of wakefulness in appropriately selected adults with narcolepsy, residual sleepiness associated with treated obstructive sleep apnoea and shift work sleep disorder. These outcomes reflect improved alertness rather than a cure for the underlying disorder.

Response varies. Some people experience a useful improvement in daytime function, while others have only a partial response or stop treatment because of headache, anxiety, nausea, insomnia or another adverse effect. Even when treatment is effective, regular review remains important to confirm that the original diagnosis is correct, the underlying sleep disorder is being managed and the benefit continues to outweigh the risks.

Modafinil has not been shown to restore every aspect of performance impaired by inadequate sleep. A person who remains sleepy must continue to avoid driving and other hazardous activities, regardless of whether a wakefulness-promoting medicine has been taken.

Established uses

Modafinil is used in adults for excessive daytime sleepiness associated with specific sleep disorders. Its established roles include the management of narcolepsy and, in suitable patients, residual sleepiness associated with obstructive sleep apnoea despite effective primary treatment. It may also be prescribed for shift work sleep disorder when the diagnosis and work pattern meet the relevant clinical criteria.

For obstructive sleep apnoea, modafinil treats persistent sleepiness rather than the airway obstruction itself. CPAP, an oral appliance, weight management, surgery or another treatment recommended for the individual must therefore continue as directed. For shift work sleep disorder, medicine should be part of a broader plan that protects adequate sleep and addresses fatigue-related workplace risks.

Modafinil is not intended as a general study aid, sports-performance product or way to extend waking time for convenience. Using it without assessment can mask an untreated cause of sleepiness and expose the person to avoidable cardiovascular, psychiatric, skin-reaction and interaction risks.

Ingredients, strengths and tablet formulation

Each Modalert tablet contains modafinil as the active ingredient. The offered strengths are 100 mg and 200 mg, and the tablets are swallowed by mouth. People with a known allergy to modafinil or any inactive tablet ingredient should not take the product. Anyone with a relevant allergy should check the exact package information for its complete ingredient list before use.

The two strengths allow a prescriber to select or adjust the total dose without changing the active medicine. They should not be treated as interchangeable on a tablet-for-tablet basis: one 200 mg tablet contains twice as much modafinil as one 100 mg tablet. Follow the prescribed strength and directions shown on the dispensing label.

General dosage principles

Dosage is determined by the diagnosed sleep disorder, response, adverse effects, age, liver function and other medicines. For narcolepsy or residual sleepiness associated with treated obstructive sleep apnoea, a commonly used adult dose is 200 mg in the morning. Some regimens use a lower dose or divide the daily amount, but changes should be made by the prescriber rather than by the patient.

For shift work sleep disorder, modafinil is generally timed before the start of the relevant work shift rather than automatically taken on waking every day. Taking it too late can interfere with planned sleep. The medicine should not be used to support repeated shifts that prevent adequate recovery sleep.

A lower dose may be needed in severe liver impairment because modafinil is mainly processed by the liver. Older adults may also require more cautious initial dosing and monitoring because elimination can be slower and other medicines or health conditions may increase the risk of adverse effects. Kidney impairment has less effect on unchanged modafinil, but severe impairment may affect the handling of its metabolites and still warrants clinical review.

If a dose is missed, taking it late in the day may cause insomnia. The appropriate action depends on the dosing schedule and how close it is to the next planned sleep period, so the dispensing directions or advice from a pharmacist or prescriber should be followed. A double dose should not be taken to compensate for a missed one.

These are educational examples of established prescribing patterns, not a personalised regimen. Do not start, stop, split or increase a dose without instructions from the clinician managing the sleep disorder.

Elimination and half-life

Modafinil is extensively metabolised in the liver. Its principal metabolites have much less pharmacological activity than the unchanged medicine, and modafinil-related material is eliminated mainly in the urine as metabolites.

The effective elimination half-life in adults is generally about 12 to 15 hours. This long half-life explains why a morning dose can continue to influence alertness into the evening and why late dosing may disrupt sleep. Regular dosing can take several days to reach a relatively stable concentration in the body.

Elimination may be prolonged in severe liver impairment and in some older adults. Interacting medicines can also alter exposure by inducing or inhibiting enzymes involved in modafinil metabolism. The half-life is a general pharmacokinetic measure and does not predict exactly when an individual will stop feeling the medicine's effects.

Important safety information

Before modafinil is started, the prescriber should know about cardiovascular disease, high blood pressure, liver or kidney impairment, anxiety, depression, bipolar disorder, psychosis, previous suicidal thoughts, alcohol or drug dependence, and every medicine or supplement being used. Blood pressure and heart rate may need assessment before and during treatment.

Pregnancy and contraception

Modafinil is contraindicated during pregnancy because its use has been associated with an increased risk of major congenital malformations. A person who is pregnant, thinks they may be pregnant or is planning pregnancy should seek medical advice promptly and should not begin treatment.

Modafinil can reduce the effectiveness of hormonal contraceptives by increasing their metabolism. An effective alternative or additional non-hormonal contraceptive method is generally required during treatment and for two months after modafinil is stopped. Contraceptive planning should be discussed with a doctor or pharmacist rather than relying on the usual hormonal method alone.

Breastfeeding

Modafinil should not be used while breastfeeding. Transfer of modafinil or its metabolites into human milk cannot be excluded, and the potential effects on a breastfed infant are not adequately established. A clinician can discuss whether another treatment or an alternative feeding plan is appropriate.

Children and adolescents

Modafinil is not recommended for people younger than 18 years. Safety and effectiveness have not been established for this age group, and paediatric studies raised concerns about serious skin reactions and psychiatric adverse effects.

Driving and hazardous work

Improved wakefulness does not necessarily mean that normal alertness has been fully restored. Modafinil can also cause dizziness, blurred vision, altered judgement or other effects that impair safe performance. Do not drive, cycle in traffic or operate machinery if sleepiness continues or the medicine causes symptoms that could affect safety.

Who should not take modafinil?

Modafinil must not be taken by anyone with known hypersensitivity to modafinil or an ingredient in the tablet. It is also contraindicated during pregnancy. Australian prescribing information additionally identifies uncontrolled moderate to severe hypertension and cardiac arrhythmias as contraindications.

Extra assessment is needed for people with other cardiovascular conditions. This includes a history of left ventricular hypertrophy or clinically significant symptoms associated with mitral valve prolapse after previous stimulant exposure. New chest pain, palpitations or unexplained shortness of breath during treatment requires prompt medical assessment.

Modafinil may provoke or worsen anxiety, agitation, mania, hallucinations, aggression or suicidal thinking in susceptible people. A history of psychosis, bipolar disorder, severe anxiety, depression or substance misuse does not automatically determine the outcome, but it requires careful prescriber assessment and monitoring. A major change in mood, thinking or behaviour should not be dismissed as a simple alerting effect.

Interactions with medicines and other substances

Modafinil can induce some liver enzymes and inhibit others, so it may reduce the effectiveness of certain medicines while increasing exposure to others. Hormonal contraceptives are a particularly important example because reduced effectiveness can result in unintended pregnancy. The prescriber and pharmacist need a complete list of prescription medicines, non-prescription products, vitamins, herbal preparations and recreational substances before treatment begins.

The clinical importance of an interaction depends on the medicines, doses and individual circumstances. A dose adjustment, laboratory monitoring, additional contraception or a different treatment may be required. Do not stop an anticoagulant, antiseizure medicine, antidepressant or other essential treatment solely because an interaction is listed; seek professional advice about the appropriate action.

Alcohol has not been adequately studied in combination with modafinil, and individual responses can be unpredictable. Other stimulants, high intakes of caffeine and sympathomimetic cold remedies may add to anxiety, insomnia, palpitations or blood-pressure effects. It is sensible to discuss these substances with the prescriber and limit them if adverse effects occur.

Adverse effects and warning signs

Headache is one of the most frequently reported adverse effects. Other common effects include nausea, reduced appetite, dry mouth, nervousness, anxiety, dizziness, indigestion, diarrhoea, back pain and difficulty sleeping. Taking the medicine at the prescribed time and avoiding additional stimulants late in the day may reduce some sleep-related problems, but persistent symptoms should be reviewed.

A rash developing during modafinil treatment requires prompt medical advice. Rare serious reactions can begin with rash, fever, mouth ulcers, facial swelling, blistering or peeling skin. Because it is not possible to predict reliably which early rashes will become severe, modafinil is generally stopped at the first sign of rash unless a clinician clearly determines that it is unrelated.

Seek emergency care for difficulty breathing, swelling of the face or throat, widespread blistering or peeling skin, fainting, severe chest pain or another sign of a serious allergic or cardiovascular reaction. Urgent assessment is also needed for hallucinations, mania, severe agitation, aggression, suicidal thoughts or a marked and unusual change in behaviour.

Suspected adverse effects can be discussed with a clinician and reported to the Therapeutic Goods Administration. Reporting is useful even when it is uncertain whether modafinil caused the event.

Overdose and poisoning

Taking more modafinil than directed can cause marked insomnia, restlessness, agitation, confusion, disorientation, anxiety, nausea, diarrhoea, tremor, palpitations, a fast or slow heartbeat, chest pain or changes in blood pressure. Symptoms can be prolonged because modafinil has a relatively long half-life.

If an overdose is suspected in Australia, call the Poisons Information Centre on 13 11 26 for immediate advice, even if no symptoms are present. Call 000 for severe symptoms, collapse, breathing difficulty, a seizure or loss of consciousness. Do not induce vomiting unless specifically instructed, and take the medicine package or dispensing information to the hospital if it is safe to do so.

Storage and disposal

Store Modalert tablets at 20°C to 25°C in a tightly closed container, away from moisture, heat and light. Keep them in a secure place out of the sight and reach of children, and do not share them with another person. Do not use tablets after the expiry date or if the packaging appears damaged.

Return unwanted or expired tablets to a pharmacy for safe disposal. Do not flush them down a toilet or place them where children, other people or animals could retrieve them.

Prescription status and our ordering policy

In Australia, modafinil is a Schedule 4 prescription-only medicine and ordinarily requires a prescription from an authorised prescriber. That national regulatory classification is separate from our ordering policy. Our checkout does not require you to submit a prescription for us to accept a Modalert order.

Our ordering process does not replace medical assessment or prescribing advice. The strength, timing and duration of treatment should still be determined by an appropriately qualified prescriber. If you need help with an order or general product information, our pharmacist-supported team is available 24/7 by email and online chat.

Benefits and limitations

For an appropriately diagnosed adult, modafinil can improve the ability to remain awake during the day or during a clinically relevant work period. Its relatively long action can make once-daily dosing practical for some people, and the availability of 100 mg and 200 mg tablets supports prescriber-directed dose selection.

These benefits have limits. Modafinil does not cure narcolepsy, correct airway obstruction in sleep apnoea or replace adequate sleep. It may not control every symptom, and its long action can become a disadvantage if it causes evening insomnia. Headache, gastrointestinal symptoms, anxiety, cardiovascular effects, clinically important interactions and rare serious skin or psychiatric reactions must also be considered.

The medicine should therefore be judged by functional benefit as well as by whether it creates a sensation of alertness. Continued severe sleepiness, unsafe driving, poor night-time sleep or the need to keep increasing the dose are reasons for clinical review rather than signs that the medicine should simply be taken more often.

Generic equivalents and therapeutic alternatives

A generic equivalent contains the same active ingredient, strength and comparable dosage form as the reference medicine. Other modafinil tablets, including the brand Provigil where available, use the same active ingredient, but their inactive ingredients, tablet appearance, approved indications and market availability may differ. A brand should not be substituted without checking the prescribed product and relevant pharmacy requirements.

Armodafinil is closely related but is not the same active ingredient. It consists primarily of one enantiomer of modafinil and is sold under brands such as Nuvigil in some markets. It should be treated as a separate medicine with its own dosing and prescribing information rather than as a tablet-for-tablet substitute.

Other wakefulness-promoting medicines include solriamfetol and pitolisant, while conventional stimulants such as methylphenidate may be considered in selected circumstances. These are therapeutic alternatives, not generic versions of Modalert. They work differently and have distinct indications, contraindications, interactions and availability.

The most suitable option depends on the diagnosed disorder, residual symptoms, cardiovascular and psychiatric history, pregnancy considerations, interacting medicines and previous treatment response. Switching medicines or changing the dose should be planned with the prescriber rather than based only on brand, package size or a perceived difference in duration.